GlassScriptPhysician profile
Lauren Teague
NPI 1144005463
$3,667.66
in general payments reported to CMS, 2019-2025
20 companies · $2,507 in 2025
The $2,507 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,161 · 2025: $2,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570 · Education: $97.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,570.42 |
| Education | $97.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $954.98 | 2024-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $441.70 | 2024-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genzyme Corporation | $432.94 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $347.04 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $184.45 | 2024-2025 | |
| Lilly USA, LLC | $161.06 | 2024-2025 | Ebglyss, Zepbound, Taltz |
| Genentech USA, INC. | $159.41 | 2024-2025 | Xolair |
| Galderma Laboratories, L.P. | $154.25 | 2024-2025 | Nemluvio |
| Abbott Laboratories | $152.55 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $147.11 | 2024-2025 | Tezspire |
| Csl Behring | $137.64 | 2024-2025 | Hizentra, Andembry |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| Biocryst US Sales Co., LLC | $60.27 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $56.67 | 2024-2025 | Cuvitru, Takhzyro |
| Abbvie INC. | $56.30 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $50.28 | 2025 | Prolastin-C Liquid, Xembify |
| Cycle Pharmaceuticals INC | $22.08 | 2025 | Sajazir |
| Pfizer INC. | $21.99 | 2025 | |
| Dermavant Sciences, INC. | $20.21 | 2024 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $17.74 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Teague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.